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Abstract
Introduction Alpha-1,3-glucosyltransferase congenital disor-
der of glycosylation (ALG6-CDG) is a congenital disorder of
glycosylation. The original patients were described with hy-
potonia, developmental disability, epilepsy, and increased
bleeding tendency.
Methods Based on Euroglycan database registration, we
approached referring clinicians and collected comprehensive
data on 41 patients.
Results We found hypotonia and developmental delay in all
ALG6-CDG patients and epilepsy, ataxia, proximal muscle
weakness, and, in the majority of cases, failure to thrive.
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Nine patients developed intractable seizures. Coagulation
anomalies were present in <50 % of cases, without spontane-
ous bleedings. Facial dysmorphism was rare, but seven pa-
tients showed missing phalanges and brachydactyly. Cyclic
behavioral change, with autistic features and depressive epi-
sodes, was one of the most significant complaints. Eleven
children died before the age of 4 years due to protein losing
enteropathy (PLE), sepsis, or seizures. The oldest patient was
a 40 year-old Dutch woman. The most common pathogenic
protein alterations were p.A333Vand p.I299Del, without any
clear genotype–phenotype correlation.
Discussion ALG6-CDG has been now described in 89 pa-
tients, making it the second most common type of CDG. It
has a recognizable phenotype and a primary neurologic
presentation.
Abbreviations
ALG6 Alpha-1,3-glucosyltransferase
CDG Congenital disorder of glycosylation
TIEF Transferrin isoelectric focusing
PLE Protein-losing enteropathy
Introduction
Congenital Disorders of Glycosylation (CDG) is a group of
inborn errors of metabolism with ~80 known biochemical sub-
types of secretory glycosylation defects. These anomalies are
easily diagnosed by plasma or serum glycan analysis (Lefeber
et al. 2011; Scott et al. 2014). After phosphomannomutase 2
(PMM2)-CDG, the second most common CDG is alpha-1,3-
Glucosyltransferase (ALG6)-CDG (previously called CDG Ic),
a defect in N-glycan assembly in the endoplasmic reticulum
(ER). ALG6-CDG is caused by an autosomal recessive defect
o f t h e enzyme Man9G l cNAc2 -P -P -Do l α - 1 , 3 -
glucosyltransferase. A genetic defect in ALG6 leads to an ac-
cumulation of Man9GlcNAc2-P-P-Dol and other lipid-linked
oligosaccharides without glucose residues and subsequent
hypoglycosylation of serum glycoproteins (Jaeken et al.
2015; Lefeber et al. 2011). Serum transferrin isoelectric focus-
ing (TIEF), or/and mass-spectrometric analysis of transferrin
glycoforms, is the first step in the screening analysis. Further
analysis of lipid-linked oligosaccharides is possible in fibro-
blasts. Direct genetic analysis confirms the diagnosis (Lefeber
et al. 2011).
The ALG6 gene is highly conserved throughout evolution,
from mammals to yeast. In humans, it is localized on chromo-
some 1p31.3 (MIM 603147 andMIM 604566). Missense mu-
tations p.A333V and p.I299Del are recognized as common
mutations in ALG6-CDG. Patients with these mutations were
described with a phenotype of hypotonia, speech disability,
and epilepsy (Lefeber et al. 2011). So far, its clinical course
and progression is reported in 48 ALG6-CDG patients show-
ing severe psychomotor retardation, seizures, speech disabili-
ty, some dysmorphic symptoms, and variable presence of fail-
ure to thrive, gastrointestinal features, hormonal anomalies,
coagulopathy, and elevated transaminase activities (Al-
Owain et al. 2010; Dercksen et al. 2013; Drijvers et al.
2010; Ichikawa et al. 2013; Lefeber et al. 2011; Miller et al.
2011). Unique features, such as abnormal skeletal develop-
ment and short fingers, have been described in two ALG6-
CDG patients, suggesting a possible association between skel-
etal development and the primary glycosylation defect
(Drijvers et al. 2010). In this paper, we review the clinical
presentation, neurologic features, unique features, and genetic
background of 41 patients diagnosed with ALG6-CDG.
Methods
We retrospectively evaluated the clinical data of 41 patients
diagnosed with ALG6-CDG between 1995 and 2013 either
registered by the Euroglycan database or followed by a clini-
cian involved in Euroglycanet and participating in the reported
study. Patients originated from The Netherlands, Germany,
Ireland, Belgium, France, Arabia, Turkey, Montenegro, and
South Africa (Caucasian). Patients with mixed ethnic back-
grounds originated from Brazil, Portugal, North Africa and
Italy. Metabolic physicians caring for these patients were
approached through the Euroglycan patient registration data-
base (University of Leuven) and the national metabolic patient
registry in The Netherlands.
Diagnostic criteria included a biochemically confirmed N-
glycosylation disorder with lipid-linked oligosaccharide pre-
cursor (LLO) results typical for an ALG6 defect and/or con-
firmed by mutation analysis. From this cohort, 35 patients
have never been reported, and six were recently reported but
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the authors offered follow-up data (Al-Owain et al. 2010;
Dercksen et al. 2013). Six patients with insufficient data (no
availability of results of mutation analysis but with type I
TIEF profile and characteristic LLO abnormalities for
ALG6) were excluded from the genotype–phenotype analysis.
Clinical data of these patients were included for clinical data
evaluation and long-term prognosis assessment, even when
mutation results were not available.
Physicians of participating patients were interviewed by a
standard questionnaire. Patients’ medical history, genetic in-
formation, and all clinical features, which have been previous-
ly observed in different forms of CDG-I, were included in our
survey. Further information was requested upon receiving in-
formation on unusual features. Certain questions were adapted
for specific age groups (developmental assessment, intellectu-
al and speech assessments, Child-Behavior Checklist, and
quality of life assessment). Genetic data were collected from
patients in the Euroglycan database and from participating
physicians, including additional data obtained by the survey.
Genetic data were evaluated in 35 patients enrolled in the
clinical study. Due to the presence of common mutations in
ALG6-CDG, the genotype–phenotype correlation was ana-
lyzed by dividing the patients into three groups: p.A333V
homozygous patients, p.A333V compound heterozygous pa-
tients, and patients homozygous for a severe mutation. A mu-
tation was labeled a priori as severe according to previously
reported severe or deleterious phenotypic expression and ac-
cording to type and localization of the mutation in the ALG6
gene (Dercksen et al. 2013).
We additionally evaluated the roles of the p.F304S muta-
tion, which has been hypothesized to be a variant in ALG6,
affecting PMM2 gene expression, PMM2-CDG phenotype
severity (Westphal et al. 2000), and the role of the known
ALG6 gene polymorphism p.Y131H. This variant is hypoth-
esized to influence glycosylation (Supplementary Table 1).
Results
Clinical features
We obtained clinical data from 41 ALG6-CDG patients, includ-
ing information on psychomotor development, growth, neuro-
logical problems, other organ involvement, systemic manifesta-
tions, malformations, and dysmorphic features or additional
symptoms (Figs. 1, Tables 1, 2, 3 and 4). Six of these 41 patients
had no mutation data available. Most patients (32) were of
Caucasian background. At the time of inquiry, mean patient
age was 11 years and 8 months. Two patients were first cousins;
otherwise, patients were unrelated. (There is a possible genetic
founder effect in the South African group). Eleven patients died
in the first 4 years of life due to sepsis, protein-losing enteropathy
(PLE), or intractable epilepsy.We found abnormal development/
disability (n = 41) and hypotonia (n = 40) as the most common
symptoms. Hypotonia was always axial and was associated with
proximalmuscleweakness. Inmost cases, generalized hypotonia
was observed during the first 4–6 years of age.
Epilepsy was present in the majority of our patients (n =
30). All patients had infantile presentations presenting be-
tween the ages of 3 and 11 months. At onset, most children
had myoclonic seizures or infantile spasms. EEG showed
slowed background rhythm, and generalized epileptic activity
in most cases, except for one patient, who was almost 1 year
old at presentation and had focal seizures. The seizure pattern
changed with age, and one fourth of patients developed
therapy-resistant epilepsy. There was no clear developmental
regression in patients developing tonic/clonic or myoclonic
seizures. Intractable seizures, mostly West syndrome, and ep-
ileptic encephalopathy were described in nine of 41 patients.
Of those nine patients, two were trialed on adrenocorticotropic
hormone (ACTH) therapy, one had a ketogenic diet without
success, and the other patients were on vigabatrin, valproic
acid, and lamotrigine therapy. Electroencephalogram (EEG)
showed mostly multifocal epileptic activity, burst suppression
pattern in four cases, and status epilepticus in three. The nine
patients with intractable seizures all had severe developmental
delay and profound speech delay, most developed microceph-
aly, and there was a high lethality rate.
Additionally we found ataxia (n = 20), nystagmus (n = 18)
,and strabismus (n = 25) in about half of the patients. Only six
of the 20 patents with ataxia showed vermis hypoplasia and/or
cerebellar atrophy on magnetic resonance (MR) brain imag-
ing. Other MRI findings included brain atrophy in several
patients, corpus callosum hypoplasia in one case, and Dandy
Walker malformation with vermis hypoplasia in another one.
All patients had some degree of developmental delay,
and speech disability was present in all but one patient
older than 3 years of age (n = 34). Behavioral problems
or mood disorders occurred in 14 patients, including autis-
tic features, autism, periodic mood changes, episodes of
aggressive behavior, and sleep disturbance. Although most
of these 14 patients showed autistic features, including ab-
normal communication, difficulties with social interaction,
and recurrent episodes of repetitive behavior, only five pa-
tients were diagnosed with autism that showed classic di-
agnostic features and regression in speech and development
between the age of 3 and 4 years. Aggressive behavior,
mostly around puberty, was present in five cases. Sleep
disturbance requiring daily melatonin treatment was noted
in seven. In 25 children, failure to thrive necessitated an
increased caloric intake (special diet). Six patients had PLE.
Seven patients also had anemia, most likely due to malab-
sorption. Four PLE patients followed an elementary diet
due PLE, and two received octreotide injections to decrease
enteral protein loss. Skeletal abnormalities present in 15
children were brachydactyly, (Figure 2) arachnodactyly,
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limited extension of joints, short arms, and scoliosis. Three
patients had dilated cardiomyopathy, and one patient
hepatosplenomegaly. Dysmorphic features in 15 patients
were unspecific (deep-set eyes, bitemporal narrowing,
broad nasal bridge, short philtrum, and hypertelorism in
individual cases). Rare clinical symptoms were a short um-
bilical cord (n = 2), ptosis (n = 1), and abnormal fat distri-
bution (n = 4). Laboratory abnormalities were not systemat-
ically assessed, and most children had only screening lab-
oratory data for thyroid hormone levels, transaminase
levels, blood glucose, and bleeding time in early stages of
the disease, which was repeated only if an abnormal level
was found initially. Patients with PLE had a more extensive
workup, showing severe hypoalbuminemia, significantly el-
evated serum transaminases, low immunoglobulin G (IgG)
levels, and anemia. Two patients had recurrent hypoglyce-
mia. Hyperinsulinism was found in two other patients with
episodes of hypoglycemia. One patient had additionally de-
creased cortisol and ACTH levels. Bleeding (increased
bleeding time and easy bruising) was less common than
expected (n = 18) and were mainly subclinical. Only one
patient experienced thrombotic episodes; no comprehensive
laboratory data were available on hemostasis. Abnormal
coagulation was demonstrated mostly by a prolonged
bleeding time. Twelve patients underwent minor surgery
(strabismus operation or tooth extraction) without compli-
cations. Three of the 12 had decreased factor IX and anti-
thrombin III levels.
Genetic properties
From the 60 ALG6-CDG patients registered before 2013 by
the Euroglycan network for whom mutation data were
available, we found four thus far unreported mutations in ad-
dition to the 23 different ALG6mutations described previous-
ly (www.lovd.nl/ALG6). The four new mutations were
missense mutations located in exon 3 (p.H79R and p.A84T),
exon 5 (p.D120G), and exon 10 (p.S308N). The pathogenic
change leading to p.A333V was the most common, with 26
alleles in 15 patients, followed by p.I299Del (12 alleles in
eight patients) and c.257 + 5G > A (seven alleles in seven
patients). Homozygosity was seen with mutations related to
p.A333V, p.A84T, p.I299Del, and p.Y161C. Mutations c.257
+ 5G > A and protein changes p.Y57X, p.G227E, p.
V447SFsX44, and R18Q, were only found in compound
heterozygous patients. Alterations p.R18Q and p.Y57X were
found once. In all patients, mutation c.257 + 5G > A was
found seven times as compound heterozygous, while p.
G227E was detected five times in a compound heterozygous
form.
Genotype–phenotype analysis
For the genotype–phenotype analysis, we analyzed 22 pa-
tients who were divided into three groups based on their
genotype. Group 1 comprised 11 patients homozygous for
the change p.A333V. Group 2 comprised four p.A333V
compound heterozygous patients, and group 3 comprised
seven patients homozygous for any mutation other than
p.A333V (patients 13, 15, 19, 21, 28, 33, 34). All patients
were included for clinical analysis according to the previ-
ously described criteria. In the first group, three of the 11
patients died; in the second group, two of four; and in the
third group, one.
Fig. 1 Distribution of clinical
features in the patient cohort of 42
alpha-1,3-glucosyltransferase
congenital disorders of glycosyl-
ation (ALG6-CDG) cases
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Table 1 Information on 41
alpha-1,3-glucosyltransferase
congenital disorder of
glycosylation (ALG6-CDG) pa-
tients, including mutations
Patient Age (years) Sex Etnicity Mutation 1 Mutation 2
1a 1 M Dutch p.A333V p.A333Vc
2 16 M Dutch p.A333V p.A333V
3a 6 M Dutch p.A333V p.A333V
4 18 F Dutch p.A333V p.A333V
5 18 F Dutch p.A333V p.A333V
6 16 F Arabic p.A333V p.A333V
7 13 F Arabic p.A333V p.A333V
8 13 F Arabic p.A333V p.A333V
9a 12 F Arabic p.A333V p.A333V
10 22 M Arabic p.A333V p.A333V
11 1 M Br/prt/it p.H79R p.D120G
12a 1 M Br/Prt/It p.H79R p.D120G
13 4 M Italian p.A84T p.A84T
14 6 M French p.G227E c.347-13G > C
15 9 M Dutch p.I299del p.I299delc
16a 0 (M) Caucasian p.Y57X p.A333Vc
17 21 F Caucasian
18 17 M Dutch p.A333V p.A333V
19 9 F Dutch p.I299del p.I299del
20a 0 F Irish c.257 + 5G > A p.C303del
21a 11 M Arabic p.Y161C p.Y161C
22 8 M Belgian c.257 + 5G > A p.A333V
23 11 M Dutch
24 21 M Dutch
25 23 F Dutch
26 7 F Dutch p.I299del p.56_85del
27 5 M Dutch p.I299del p.56_85del
28 9 F Dutch p.I299del p.I299del
29 36 F Dutch
30a 5 F Dutch
31 9 M Dutch p.I299del c.257 + 5G > A
32 3 F Dutch p.A333V V447SfsX44
33 8 F Turkish p.S308N p.F304S
34 7 M Turkish p.S308N p.F304S
33 23 M Dutch p.I299del p.I299delc
34 4 M Montenegro p.A84T p.A84T
35 4 F German p.I299del p.56_85del
36 4 M Arabic p.S308N c.680 + 2 T > G
37a 0 M Caucasian p.A333V p.V447SfsX44
38a 3 M Caucasian c.257 + 5G > A p.G227E
39 3 M Caucasian c.257 + 5G > A p.G227E
40a 6 F Caucasian c.257 + 5G > A p.G227E
41 3 M Caucasian c.257 + 5G > A p.G227E
NA data not available
a Deceased
b F304S variant, a known polymorphism
c p.Y131H variant, a known polymorphism
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Neurological symptoms and developmental disability
Speech, developmental or intellectual disability, muscle in-
volvement, and hypotonia were present in all patients.
Muscle weakness, infantile seizures, and wheelchair depen-
dence was significant (≥50 % present) in all three groups. In
the group homozygous for p.A333V, all patients had severe
delay in speech development. Even patients with mild motor
delay had mostly severe speech delay or absent speech. One
patient homozygous for p.I299del and another heterozygous
for p.I299del had relatively mild speech delay. Brain
malformations were found mostly in the second group
(50 %) and ataxia mostly in groups 1 (91 %) and 3 (50 %).
Visual loss was highly represented in the p.A333V compound
heterozygous group: 75 % compared with 9 % (group 1) and
30 % (group 3). Strabismus was less frequent in group 2
(25 %), and nystagmus was unique in group 3.
Microcephaly was found most frequently in the p.A333V ho-
mozygous group: 55 % compared with groups 2 and 3 at 0 %
and 1 %, respectively.
Physical appearance
There was no correlation between a specific mutation and
dysmorphic features. Failure to thrive was common in groups
1 and 2 (82 % and 100 %, respectively). Being underweight
and of short stature were more prevalent in group 1 (82 %)
than in groups 3 (30 %) and 2 (0 % and 25 % respectively).
Systemic involvement and laboratory abnormalities
PLE was found in 75 % of compound heterozygous patients
and only in 9 % of p.A333V homozygous patients, and in no
patient homozygous for a mutation other than leading to
change p.A333V. Increased bleeding tendency was one of
the most common features, with 73 % in group 1 and 50 %
in group 3. Only one of four patients with compound hetero-
zygosity had bleeding anomaly. Hypoglycemia and increased
serum transaminases were also most prevalent in p.A333V
homozygous patients. In summary, the most severe phenotype
was observed in p.A333V homozygous patients and com-
prised hypotonia, intellectual disability, severe proximal mus-
cle weakness, seizures, visual or hearing loss, failure to thrive,
and PLE; however, the relatively small group 2 had the
highest mortality rate. The patient with a severe neurological
phenotype carrying the frameshift mutation p.V447SfsX44
died within the first 5 months of life due to intractable PLE.
We found the additional presence of the p.F304S variant in
one patient in our cohort, without any specific correlation with
ALG6-CDG phenotype severity. Although the pathogeneicity
of the p.F304S variant has been debated before, due to its very
high frequency and low conservation, it has been defined as a
polymorphism (Vuillaumier-Barrot et al. 2001;Westphal et al.Ta
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2003). The only patient carrying this alteration additional to
the p.I299del homozygous state has a phenotype that is com-
parable with other p.I299del-homozygous patients. The addi-
tional presence of p.Y131H, which is a known polymorphism,
showed no correlation with the phenotype in our patients with
ALG6-CDG. The variant was found in three patients with
different genotypes, and no correlation was detected with phe-
notype severity (Goreta et al. 2012) (Supplementary Table 1).
Discussion
In this paper, we redefine the phenotype of ALG6-CDG in 41
patients. In this patient cohort, the most common pathogenic
changes were p.A333V and p.I299Del. Patients homozygous
for p.A333V seemed to have the most severe presentation and
the most multisystem involvement, but the subgroups were
small, and we found no clear genotype–phenotype correlation.
Phenotypic variability was present between siblings as well.
Epilepsy is reported in >70 % of patients, and in our
cohort, it presented as one of the most frequent neuro-
logical features, appearing in infancy and intractable in
one fourth of patients. Besides the previously reported
triad of hypotonia, developmental disability, and sei-
zures, we also found a high percentage of other neuro-
logical symptoms, including absent speech, ataxia, prox-
imal muscle weakness, and visual loss. Several patients
had behavioral abnormalities, including autistic behav-
ior, mood swings, and periods of inertia alternating with
periods of aggressive behavior, which is unusual for
most CDG-I patients. Special features included facial
dysmorphism, cardiomyopathy, and limb malformations
in several patients. Some patients had severe distal limb
reduction. Abnormal fat distribution was present in few
patients. Laboratory abnormalities were present in aboutTa
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Fig. 2 Distal limb malformation in a patient with Brachydactyly of the
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half of the patients, although not all patients were
screened systematically. Anemia was common as well.
The most common alteration was an increased bleeding
time, although less than half of the ALG6-CDG patients
showed an increased bleeding tendency. In some early-
onset cases with severe multisystem involvement, PLE,
hypoalbuminemia, hypoglycemia, and frequent infec-
t ions were present and led to ear ly le thal i ty.
Interestingly, no fetal edema or fetal hydrops was ob-
served in this cohort.
Some patients showed stagnation in psychomotor de-
velopment around puberty, but there was no clear re-
gression. Most patients are still young, which makes
long-term prognosis difficult. A few older patients
(12–16 years) developed significant behavioral abnor-
malities in this period, and some of them developed
hypothyroidism or had new-onset of episodes of hypo-
glycemia. According to our data, most ALG6-CDG pa-
tients reached puberty and a few reached adulthood. The
oldest patient was a 40-year-old Dutch woman. She was
able to make some steps independently, had mild speech
disability, and had static encephalopathy. PLE, one of
the most significant life-threatening symptom of
ALG6-CDG, was successfully treated with a low-fat/el-
ementary protein diet and subcutaneous treatment with
octreotide. Anemia was a frequent comorbidity. Chronic
intestinal protein loss and hypogammaglobulinemia
might lead to early lethality in young ALG6-CDG pa-
tients. We found a high percentage of associated labo-
ratory abnormalities in our patients, necessitating pro-
spective, regular screening of glycemia, coagulation,
and endocrine and liver function.
We detected the mutations p.A333V and p.I299del in half
of our patients, Allele frequencies for the most common mu-
tations in our patient group, according to the Exome
Aggregation Consortium (ExAC) database (http://exac.
broadinstitute.org/), is at 0.00006595 for p.A333V and 0.
000008268 for p.I299del. Surprisingly, for c.257 + 5G > A,
database frequency was as high as 0.0004560. While the
relative frequency of p.A333V and p.I299del were
somewhat comparable to the database’s allele frequency, we
encountered in proportion significantly less patients with the
mutation c.257 + 5G > A compared with that previously
reported.
Including patients in our cohort, there are 89 ALG-CDG
patients reported in the literature (Jaeken et al. 2015), and the
ALG6 defect remains the second most common CDG type,
with a recognizable phenotype. Since some children only
present with hypotonia and seizures, or behavioral
abnormality and speech disability, we recommend systematic
glycosylation screening in developmental disability.
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